MOR vs. CTLT, ROIV, ELAN, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
MorphoSys (NASDAQ:MOR) and Catalent (NYSE:CTLT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
MorphoSys has higher earnings, but lower revenue than Catalent. Catalent is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
MorphoSys currently has a consensus target price of $11.78, indicating a potential downside of 36.26%. Catalent has a consensus target price of $53.14, indicating a potential downside of 2.48%. Given Catalent's higher probable upside, analysts clearly believe Catalent is more favorable than MorphoSys.
18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 0.3% of Catalent shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Catalent has a net margin of -26.61% compared to MorphoSys' net margin of -226.79%. Catalent's return on equity of -2.73% beat MorphoSys' return on equity.
MorphoSys has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
In the previous week, MorphoSys had 3 more articles in the media than Catalent. MarketBeat recorded 6 mentions for MorphoSys and 3 mentions for Catalent. Catalent's average media sentiment score of 1.39 beat MorphoSys' score of 0.70 indicating that Catalent is being referred to more favorably in the news media.
Catalent received 615 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 59.20% of users gave Catalent an outperform vote while only 38.46% of users gave MorphoSys an outperform vote.
Summary
Catalent beats MorphoSys on 10 of the 17 factors compared between the two stocks.
Get MorphoSys News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MorphoSys Competitors List
Related Companies and Tools
